Mitochondrial DNA Market – Trends, Growth & Forecast 2023-2033

Mitochondrial DNA Market Snapshot (2023 to 2033)

The global mitochondrial DNA market was estimated to reach a valuation of USD 316.8 Million in the year 2022. With a steady CAGR of 7.5% from 2023 to 2033, this market is expected to reach USD 323.2 Million by 2023 and USD 527.9 Million by 2033.

The regulation of apoptosis, cellular metabolism, as well as oxidative stress management is all critical functions of mitochondria. Mitochondrial DNA (mtDNA) possesses a variety of unique characteristics, including maternal inheritance, a significant number of copies inside a cell, and a significant mutation rate, which have drawn the attention of researchers in a variety of disciplines.

When studying expansions, migrations, and other patterns of gene flow, mtDNA helps trace the geographic distribution of genetic diversity. The use of mtDNA in forensic science is widespread. It is an effective tool for locating human remains. The worldwide mitochondria DNA market is anticipated to increase more quickly between 2023 and 2033 as a result of this sort of DNA's widespread use.

Additionally, mtDNA exhibits a high incidence of mutations and polymorphisms. Some of these conditions, such as oxidative phosphorylation (OXPHOS) abnormalities, Type 2 diabetes, maternally inherited diabetes and deafness (MIDD), heart failure, neurodegenerative conditions, and cancer, are becoming recognized as significant contributors to human pathology. These kinds of symptoms may be utilized to accurately diagnose disorders, which is driving the mitochondrial DNA market's sales.

Increased genetic transmission capacity to the next generation and rising frequency of mitochondrial illnesses that cause considerable morbidity and death are some factors anticipated to propel the expansion of the worldwide mitochondrial DNA market during the forecast period. Over ten out of every 100,000 persons in 2019 have mitochondrial diseases, which frequently manifest themselves for the first time in early life, according to the Wellcome Center for Mitochondrial Research

According to statistics from the Genetic and Rare Disease Information Center, women with mitochondrial genetic illnesses have a 50% chance of passing along this changed gene to kids with each pregnancy, indicating a rising burden of this disease.

Additionally, during the forecast period, the existence of several clinical studies carried out by various research institutions to address the unmet needs of patients with mitochondrial illnesses is anticipated to propel the growth of the worldwide mitochondrial DNA market.

For instance, in April 2018, GenSight Biologics-a biopharmaceutical company that specializes in the development and discovery of novel gene therapies for retinal neurodegenerative diseases and disorders of the central nervous system-announced the findings from the REVERSE clinical trial in Phase III, which assessed the effectiveness and safety of one intravitreal injection of GS010 (rAAV2/2-ND4) to treat the mitochondrial disease Leber Hereditary Optic Neuropathy. (LHON). These discoveries are expected to increase the demand for mitochondrial DNA globally.

The global mitochondrial DNA market is anticipated to rise throughout the forecast period as a result of increased spending in R&D by organizations to aid researchers in developing effective treatments for addressing patients' unmet medical requirements. By funding focused therapeutic discovery projects, for example, the Foundation for Mitochondrial Medicine (FMM) promotes and supports the development of the majority of possible mitochondrial DNA therapies, research, and for the treatment of different forms of mitochondrial disease and disorder.

The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the FMM worked together to sponsor a research initiative from the Mayo Clinic Department of Neuroscience to look into a mitochondrial-targeted therapy strategy to treat Parkinson's disease.

North America is predicted to hold a significant market share due to the increased frequency of this condition, the expansion of initiatives to raise awareness of it and assist the development of innovative medications, and the region's dominance in the market for mitochondrial DNA over the projection period.

Data Point	Key Statistics
Expected Market value in 2023	USD 323.2 Million
Expected Market value in 2033	USD 527.9 Million
Growth Rate (2023 to 2033)	7.5%

Mitochondrial DNA Market Overview

Mitochondria present in a human cell is responsible for converting food into energy in body. Mutations of mitochondrial DNA can lead to several illnesses that cause poor growth, muscle weakness, learning disabilities, increased risk of infection, respiratory problem and many more.

Mitochondrial disorders are rare and chronic affecting several body parts like nerves, heart, kidney, liver and pancreas. Some disorders caused due to excess mitochondrial DNA mutation are Leber’s hereditary optic neuropathy, Leigh syndrome, mitochondrial myopathy, mitochondrial DNA depletion syndrome and others.

According to the National Institute of Health (NIH), mitochondrial disease is a type of genetic disease with a minimum prevalence of greater than 1 in 5000 people across the globe.Covid-19 has led to lockdown in several countries delaying manufacturing activities in mitochondrial DNA market.

There has been observed supply chain disruption due to restrictions laid on trading across borders by various countries. The significant decline in hospital visits and the treatment-seeking rate will impact mitochondrial DNA market. Leading biopharmaceuticals are inclined towards developing coronavirus cure, delaying other clinical trials impact the growth rate of mitochondrial DNA market.

Mitochondrial DNA Market: Drivers and Restraints

The rise in the prevalence of mitochondrial disorders increases the demand for mitochondrial DNA market. Clinical stage development biopharmaceuticals attract investments from private players leading to an expansion of mitochondrial DNA market.

For instance, In June 2018, Stealth Biotherapeutics Corp. announced USD 100 million funds being raised from investors to develop and commercialize Elamipretide drug used as therapeutic for mitochondrial myopathy which is caused due to mutations in mitochondrial DNA.

Advancement in technology and research and development activities is expected to fuel mitochondrial DNA market growth. Lack of awareness about therapeutic options available for mitochondrial dysfunction is expected to hinder mitochondrial DNA market growth. The stringent regulatory requirement for drug approval is a challenging factor for mitochondrial DNA market growth.

Mitochondrial DNA Market: Overview 

NSAIDs is expected to hold a major revenue share of mitochondrial DNA market during the forecast period. Therapeutic application is expected to dominate the mitochondrial DNA market during the forecast period with an increasing prevalence of mitochondrial disorders.

Diagnostic application in mitochondrial DNA market holds a significant share due to its ability to help detect cancer. Oral drugs are most common for mitochondrial DNA market. Whereas, hospital pharmacies is the largest distribution channel for mitochondrial DNA market. Increased adoption of e-commerce is will increase the demand for online pharmacies in mitochondrial DNA market.

Mitochondrial DNA Market: Region-wise Outlook

North America will continue to dominate the mitochondrial DNA market in the coming decade with a high rate of prevalence of mitochondrial disorders. The high rate of approvals and commercialization of pharmaceutical drugs increases the demand for mitochondrial DNA market in North America.

Europe is the second leading region in the mitochondrial DNA market with increased investments towards drug development and advanced technology. Asia-pacific is lucrative market with a higher growth rate in the mitochondrial DNA market during the forecast period with a large patient population in the region and increasing healthcare expenditure.

The Middle East and Africa are expected to observe the least growth in mitochondrial DNA market due to poor healthcare infrastructure and economic conditions in the region. 

Mitochondrial DNA Market: Key Market Participants

Major players in mitochondrial DNA market include

• Pfizer Inc. 
• Novartis AG 
• Takeda Pharmaceuticals
• Amgen Inc.
• NeuroVive Pharmaceutical AB
• Entogene AG
• Stealth Biotherapeutics
• Ixchel Pharma 
• Reata Pharmaceuticals 
• Khondrion BV 
• Alkeus Pharmaceuticals 
• Intercept Pharmaceutics

The research report on mitochondrial DNA market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on mitochondrial DNA market provides analysis and information according to market segments such as drug class, route of administration, application, and region.

The report covers exhaust analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America (the USA, Canada)
• Latin America (Mexico, Brazil)
• Europe (Germany, Italy, France, the United Kingdom, Spain, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain.

The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Table of Content

• 1. Executive Summary
• 2. Industry Introduction, including Taxonomy and Market Definition
• 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
• 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
• 5. Pricing Analysis
• 6. Global Market Analysis and Forecast
  • 6.1. By Drug Type
  • 6.2. By Application
  • 6.3. By Route Of Administration
  • 6.4. By Distribution Channel
• 7. Global Market Analysis and Forecast, By Drug Type
  • 7.1. Anti-inflammatory Biologics
  • 7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.3. Corticosteroids
• 8. Global Market Analysis and Forecast, By Application
  • 8.1. Therapeutic
  • 8.2. Research and development
  • 8.3. Diagnostic
• 9. Global Market Analysis and Forecast, By Route Of Administration
  • 9.1. Oral
  • 9.2. Intravenous
• 10. Global Market Analysis and Forecast, By Distribution Channel
  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies
  • 10.3. Drug Stores
  • 10.4. Online Pharmacies
• 11. Global Market Analysis and Forecast, By Region
  • 11.1. North America
  • 11.2. Latin America
  • 11.3. Europe
  • 11.4. East Asia
  • 11.5. South Asia
  • 11.6. Oceania
  • 11.7. Middle East & Africa
• 12. North America Sales Analysis and Forecast, by Key Segments and Countries
• 13. Latin America Sales Analysis and Forecast, by Key Segments and Countries
• 14. Europe Sales Analysis and Forecast, by Key Segments and Countries
• 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries
• 16. South Asia Sales Analysis and Forecast, by Key Segments and Countries
• 17. Oceania Sales Analysis and Forecast, by Key Segments and Countries
• 18. Middle East & Africa Sales Analysis and Forecast, by Key Segments and Countries
• 19. Sales Forecast by Drug Type, Application, Route Of Administration, and Distribution Channel for 30 Countries
• 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
• 21. Company Profile
  • 21.1. Pfizer Inc.
  • 21.2. Novartis AG
  • 21.3. Takeda Pharmaceuticals
  • 21.4. Amgen Inc.
  • 21.5. NeuroVive Pharmaceutical AB
  • 21.6. Entogene AG
  • 21.7. Stealth Biotherapeutics
  • 21.8. Ixchel Pharma
  • 21.9. Reata Pharmaceuticals
  • 21.10. Khondrion BV
  • 21.11. Alkeus Pharmaceuticals
  • 21.12. Intercept Pharmaceutics